Cancer immunotherapy
PRINCIPAL INVESTIGATORS
- Rafael Moreno Olié
CLINICAL RESEARCHERS
- Oscar Buisán Rueda
POSTDOCTORAL RESEARCHERS
- Marcel Costa Garcia
- Gabriel Espinosa Carrasco
- Lidia Franco Luzon
PREDOCTORAL RESEARCHERS
- Luis Paul Del Carpio Huerta
- Laura Moya Borrego
- Sebastian Ciro Carne Martin
- Pau Fiol Mata
- Juan Antonio Marin Jimenez
- Carla Perez Vazquez
SCIENTIFIC SUPPORT
- Carles Codony Servat
- Silvia Torres Manjon
- Ainhoa Muñoz Metrino
Cancer
Oncobell
Scientific production
23
PAPERS
Average IF: 15,99
9
LED PAPERS
Average IF: 13,86
10 PUBLICATIONS IN FIRST DECILE
18 PUBLICATIONS IN FIRST QUARTILE
16 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Piulats,JM;Watkins,C;Costa García,M;Del Carpio,L;Piperno Neumann,S;Rutkowski,P;Hassel,JC et al, Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis., Ann. Oncol., 2024;35(3):317-326, doi:10.1016/j.annonc.2023.11.013
- Costa Garcia,M;Rojas,JJ;Ramos,MD;Barlabé,P;Calvo,P;Navas,J;Alemany,R et al, Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors, Cancer Immunol Immunother, 2024;73(1):5-5, doi:10.1007/s00262-023-03611-3
- Morris,MJ;Castellano,D;Herrmann,K;de Bono,JS;Shore,ND;Chi,KN;Crosby,M et al, 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial, Lancet, 2024;404(10459):doi:10.1016/S0140-6736(24)01653-2
- Costa Garcia,M;Moya Borrego,L;Bonastre,RA;Olié,RM, Optimized protocol for culturing menstrual blood-derived MSCs for combination with oncolytic adenoviruses in cancer treatment, Mol. Ther. Oncol., 2024;32(4):200907-200907, doi:10.1016/j.omton.2024.200907
- Vigués,F;Etcheverry,B;Reggeti,J;Gaya,JM;Territo,A;Gallioli,A;Berquin,C et al, Orthotopic Robot-assisted Kidney Transplantation: Surgical Technique and Preliminary Results, Eur Urol, 2024;85(6):556-564, doi:10.1016/j.eururo.2024.03.037
Research highlights
PROJECTS
4 Granted Competitive project
13 Ongoing Competitive projects
2 Started clinical trials
30 Ongoing clinical trials
2 Started non competitive project
2 Ongoing non competitive project
INNOVATION
4 Patents
PUBLISHED WORKS
1 Guideline
NETWORKS
RICORS TERSV
AdenoNet
CIBERONC
AGAUR-SGR 2021 00895
Selected projects
- PI24/01710. Identificación de debilidades inmunes del cáncer de próstata metastásico. INMUNE-PC. Instituto de Salud Carlos III (ISCIII). Budget: 315.000€. 2025-2027. PI: Piulats Rodríguez, Josep María.
- RD21/0017/0012. RICORS TERAV. Instituto de Salud Carlos III (ISCIII). Budget: 170.999,99€. 2022-2025. PI: Alemany Bonastre, Ramón.
- PI23/00385. Células troncales mesenquimales como vehículo celular de un adenovirus oncolitico codificante de un activador biespecifico de célula T (BiTE) frente a EGFR para el tratamiento del glioblastoma.. Instituto de Salud Carlos III (ISCIII). Budget: 95.625€. 2024-2026. PI: Moreno Olié, Rafael.
- CLIP-CRI-2022. Generation of personalized TCR therapy against GNAQ/11 Q209L mutations in Uveal Melanoma. PREMI-UM. CANCER RESEARCH INSTITUTE CRI. Budget: 182.848,77€. 2023-2025. PI: Piulats Rodríguez, Josep María.
- PID2023-146637OB-C21. Fomentar la inmunidad antitumoral con adenovirus oncolíticos armados con proteínas formadoras de poros o epítopos formadores de tríadas. Ministerio de Ciencia e Innovación. Budget: 262.500€. 2024-2027. PI: Alemany Bonastre, Ramón.